Thursday, July 31, 2014 6:05:10 PM
The market was expecting LymPro numbers for sensitivity and specificity that would clearly make it the "gold standard" for Alzheimer's detection. Unfortunately it appears that in diagnostic terms it was marginally better than a "coin-flip".
Here again this is my opinion and I'm not qualified as a scientist to extrapolate the available information to a meaningful conclusion. I'll let others on the board do that.
As for increasing the number of authorized shares by 50% or a 100% I don't see another alternative but then again I'm not a financial type individual. I am barely able to balance my checkbook.
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM